iThei mdcdaelcinfd o c elllllrllll mmthsl mbThkThhpswith anatabine at a dose of 9–24 mg per day, while the rest were treated
with a placebo.
The results showed a statistically significant reduction in thyroglobulin
antibodies (TgAbs) at weeks four, eight, and twelve. TgAbs were reduced
by an average of 46 points in the treatment group as compared with a
4-point reduction in the placebo group. Half the patients reduced their
antibodies by at least 25 points, while 25 percent reduced their TG anti-
bodies by at least 100 points.
All of the patients in the study were euthyroid, meaning their TSH, T4,
and T3 were within normal range, either because they were taking levothy-
roxine or because they were in the early stages of Hashimoto’s. Anatabine
did not affect the levels of TSH, T4, or T3, but the patients taking le-
vothyroxine experienced a greater reduction in antibodies than patients
who were not.
Dizziness, nausea, tingling, and headaches were some of the more com-
mon side effects.
Surprisingly, in contrast to case studies that showed a reduction in TPO
antibodies, this particular study did not find a statistically significant re-
duction in TPO antibodies (meaning not everyone studied saw a ben-
efit). The manufacturer, however, provided a few case studies of individu-
als who did see a reduction in TPO antibodies.
Here is one of the most compelling case studies:
One patient studied experienced an enormous drop in antibody levels
after taking a dose of 0.12 mg/kg of anatabine daily for sixteen days. Her
TPO antibodies reduced from 3,655 IU to 300 IU.
The authors of the study noted that TG antibodies are often the first
antibodies to come down, followed by TPO antibodies. They thought
perhaps more time was needed to see a statistically significant drop in
TPO antibodies.
Doses of 0.12–0.267 mg/kg a day have been studied and found safe and
effective in reducing thyroid antibodies. This dose would equate to about
5–12 mg daily for a 100-pound woman. Anatabine has a half-life of
about eight hours and should be dosed six to eight hours apart to ensure
a constant level in the body.
Anatabine should be started at a low dose of 1–2 mg a day and gradually
increased to the target dose over a week. The onset of action should be seen